{"title":"Bei myelodysplastischen Syndromen (MDS): Mit Azacitidin möglichst lange behandeln!","authors":"","doi":"10.1055/s-0030-1254863","DOIUrl":"https://doi.org/10.1055/s-0030-1254863","url":null,"abstract":"","PeriodicalId":123656,"journal":{"name":"Tumordiagn u Ther","volume":"100 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2010-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121113189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Signifikant längeres Überleben mit Bortezomib in der Primärtherapie und im Rezidiv - Neudefinitionen von Behandlungsendpunkten","authors":"","doi":"10.1055/s-0030-1254861","DOIUrl":"https://doi.org/10.1055/s-0030-1254861","url":null,"abstract":"","PeriodicalId":123656,"journal":{"name":"Tumordiagn u Ther","volume":"33 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2010-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"129282425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
. Abstract ! The current article reviews a novel approach in tumor therapy based on peptide hormon analogs of GnRH, Bombesin/GRP and Somatostatin as carrier substances for cytotoxic agents, thus aiming to achieve a higher concentration of the active compound in the vicinity of the tumor. This therapeutic concept should lead to an increased antitumoral efficacy and minimized side effects. Targeted therapy with cytotoxic analogs of GnRH, Bombesin/GRP and Somato-statin has been highly effective in preclinical tumor models of breast, endometrial, and ovarian cancer, although associated with only a low haematological toxicity. In the current studies cytotoxic hybrid molecules were significantly more potent than the chemotherapeutic agent alone. However, the expression of the respective target receptor on the tumor cells is a necessary requirement for an effective therapy, as blockade of tumoral receptors significantly decreased the efficacy of the cytotoxic hybrid molecules in vivo. The haematological toxicity of targeted chemotherapy was significantly less pronounced than the corresponding nondirect-ed therapy with a cytotoxic radical alone in all animal experiments. The rapid development of a resistance to targeted chemotherapy is unlikely, as the expression of MDR proteins after targeted therapy was not increased as compared to a corresponding non-targeted approach in all experiments. AN-152, one of the compounds investigated in this article has already entered clinical testing. Thus, AN-152 showed a good tolerability in a clinical phase I study for patients with GnRH-positive breast, ovarian, and endometrial cancer and is now tested for efficacy in a clinical phase II study
{"title":"Rezeptorvermittelte Chemotherapie gynäkologischer Tumoren und des Mammakarzinoms","authors":"J. Engel1, A. Schally2, A. Honig1, J. Dietl1","doi":"10.1055/s-0029-1245359","DOIUrl":"https://doi.org/10.1055/s-0029-1245359","url":null,"abstract":". Abstract ! The current article reviews a novel approach in tumor therapy based on peptide hormon analogs of GnRH, Bombesin/GRP and Somatostatin as carrier substances for cytotoxic agents, thus aiming to achieve a higher concentration of the active compound in the vicinity of the tumor. This therapeutic concept should lead to an increased antitumoral efficacy and minimized side effects. Targeted therapy with cytotoxic analogs of GnRH, Bombesin/GRP and Somato-statin has been highly effective in preclinical tumor models of breast, endometrial, and ovarian cancer, although associated with only a low haematological toxicity. In the current studies cytotoxic hybrid molecules were significantly more potent than the chemotherapeutic agent alone. However, the expression of the respective target receptor on the tumor cells is a necessary requirement for an effective therapy, as blockade of tumoral receptors significantly decreased the efficacy of the cytotoxic hybrid molecules in vivo. The haematological toxicity of targeted chemotherapy was significantly less pronounced than the corresponding nondirect-ed therapy with a cytotoxic radical alone in all animal experiments. The rapid development of a resistance to targeted chemotherapy is unlikely, as the expression of MDR proteins after targeted therapy was not increased as compared to a corresponding non-targeted approach in all experiments. AN-152, one of the compounds investigated in this article has already entered clinical testing. Thus, AN-152 showed a good tolerability in a clinical phase I study for patients with GnRH-positive breast, ovarian, and endometrial cancer and is now tested for efficacy in a clinical phase II study","PeriodicalId":123656,"journal":{"name":"Tumordiagn u Ther","volume":"63 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2010-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115739944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
H. Wengenmair, J. Kopp, H. Vogt, J. Sciuk, D. R. N. H. Wengenmair, Medizinische Physik und Strahlenschutz, Klinikum Augsburg, Gammasonde · Wchterlymphknoten, PET-Sonde · Qualitts-kriterien
Measurement principles for gamma probes for localizing radioactively labelled tissues are described. Methods for low energy radiation emitting nuclides ( 99m Tc,140 keV) are discussed as well as for high energy radiation nuclides ( 18 F, 511 keV). Regarding the localization of 99m Tc-labelled sentinel lymph nodes minimal requirements based on defined quality criteria were derived. The quality criteria of gamma probes available in Germany were determined. As a result of this it became clear that also gamma probes are used which performance characteristics are not adapted to the situation in sentinel lymph node diagnostics. The suitability of these probes to reliably localize SLN is doubtful.
{"title":"Gammasonden zur intraoperativen Lokalisierung von radioaktiv markierten Wächterlymphknoten, Tumoren und Metastasen","authors":"H. Wengenmair, J. Kopp, H. Vogt, J. Sciuk, D. R. N. H. Wengenmair, Medizinische Physik und Strahlenschutz, Klinikum Augsburg, Gammasonde · Wchterlymphknoten, PET-Sonde · Qualitts-kriterien","doi":"10.1055/s-2006-927040","DOIUrl":"https://doi.org/10.1055/s-2006-927040","url":null,"abstract":"Measurement principles for gamma probes for localizing radioactively labelled tissues are described. Methods for low energy radiation emitting nuclides ( 99m Tc,140 keV) are discussed as well as for high energy radiation nuclides ( 18 F, 511 keV). Regarding the localization of 99m Tc-labelled sentinel lymph nodes minimal requirements based on defined quality criteria were derived. The quality criteria of gamma probes available in Germany were determined. As a result of this it became clear that also gamma probes are used which performance characteristics are not adapted to the situation in sentinel lymph node diagnostics. The suitability of these probes to reliably localize SLN is doubtful.","PeriodicalId":123656,"journal":{"name":"Tumordiagn u Ther","volume":"6 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2006-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128755158","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Das hepatozellulare Karzinom (HCC) ist weltweit einer der haufigsten malignen Tumoren mit steigender Inzidenz auch in westlichen Landern. Das HCC wird typischerweise erst relativ spat im Verlauf diagnostiziert und bis auf wenige Ausnahmen ist die Prognose ungunstig. Potenziell kurative Therapieansatze sind die Tumorresektion und in ausgewahlten Fallen die Lebertransplantation. Diese chirurgischen Verfahren kommen aber aufgrund des Tumorstadiums oder der Leberfunktion fur einen Grosteil der Patienten nicht infrage. Weitere nichtchirurgische Therapieverfahren wie Radiofrequenzthermo- und Kryoablation, Alkohol- oder Saureinjektionen, transarterielle Chemoembolisationen, Strahlentherapie und systemische Chemotherapie konnen einzeln oder in Kombination in den verschiedenen Stadien der Erkrankung eingesetzt werden, um eine Verlangerung des (rezidivfreien) Uberlebens und in wenigen Fallen auch eine Heilung zu erzielen. Hepatocellular carcinoma is one of the most common cancers worldwide. The incidence of this disease is also increasing in the Western world. Typically, HCC is diagnosed when patients have already reached an advanced stage of the disease and the prognosis is poor. Potentially curative treatment options include surgical resection or liver transplantation and can be offered to patients with adequate liver function and tumour stage. Other non-surgical treatment options such as radiofrequency ablation, cryoablation, ethanol or acetic acid injection, transarteriel chemoembolisation radiation therapy and systemic chemotherapy can be offered either alone or in combination to selected groups of patients. These treatments can improve (tumour-free) survival and in a few cases even cure the patient.
{"title":"Therapie des hepatozellulären Karzinoms","authors":"T. Greten, H. Blum, M. Manns, M. Geissler","doi":"10.1055/s-2006-927039","DOIUrl":"https://doi.org/10.1055/s-2006-927039","url":null,"abstract":"Das hepatozellulare Karzinom (HCC) ist weltweit einer der haufigsten malignen Tumoren mit steigender Inzidenz auch in westlichen Landern. Das HCC wird typischerweise erst relativ spat im Verlauf diagnostiziert und bis auf wenige Ausnahmen ist die Prognose ungunstig. Potenziell kurative Therapieansatze sind die Tumorresektion und in ausgewahlten Fallen die Lebertransplantation. Diese chirurgischen Verfahren kommen aber aufgrund des Tumorstadiums oder der Leberfunktion fur einen Grosteil der Patienten nicht infrage. Weitere nichtchirurgische Therapieverfahren wie Radiofrequenzthermo- und Kryoablation, Alkohol- oder Saureinjektionen, transarterielle Chemoembolisationen, Strahlentherapie und systemische Chemotherapie konnen einzeln oder in Kombination in den verschiedenen Stadien der Erkrankung eingesetzt werden, um eine Verlangerung des (rezidivfreien) Uberlebens und in wenigen Fallen auch eine Heilung zu erzielen. Hepatocellular carcinoma is one of the most common cancers worldwide. The incidence of this disease is also increasing in the Western world. Typically, HCC is diagnosed when patients have already reached an advanced stage of the disease and the prognosis is poor. Potentially curative treatment options include surgical resection or liver transplantation and can be offered to patients with adequate liver function and tumour stage. Other non-surgical treatment options such as radiofrequency ablation, cryoablation, ethanol or acetic acid injection, transarteriel chemoembolisation radiation therapy and systemic chemotherapy can be offered either alone or in combination to selected groups of patients. These treatments can improve (tumour-free) survival and in a few cases even cure the patient.","PeriodicalId":123656,"journal":{"name":"Tumordiagn u Ther","volume":"29 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2006-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132040105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
N. Ewald, M. Toepler, A. Akinci, H. Kloer, R. Bretzel, P. Hardt
Einleitung: Material und Methodik: Ergebnisse: Diskussion: Introduction: Methods: Results: Conclusions:
引言:材料和方法:结果:讨论:方法:结果:
{"title":"Pyruvatkinase M2 (Tumor M2-PK) im Stuhl als Screeningparameter für kolorektale Neoplasien. Eine Übersicht über bisher publizierte Daten","authors":"N. Ewald, M. Toepler, A. Akinci, H. Kloer, R. Bretzel, P. Hardt","doi":"10.1055/s-2006-927041","DOIUrl":"https://doi.org/10.1055/s-2006-927041","url":null,"abstract":"Einleitung: Material und Methodik: Ergebnisse: Diskussion: Introduction: Methods: Results: Conclusions:","PeriodicalId":123656,"journal":{"name":"Tumordiagn u Ther","volume":"78 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2005-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125854196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
M. Brück, U. Nixdorf, H. V. Korn, R. Feyrer, T. Papadopoulos, G. Helm, R. Janka, C. Mardin, V. Strnad, W. Daniel
Zentralarterienverschluss – kirschroter Fleck – Amaurosis – Papillenatrophie Non-Hodgkin(cid:29)s Lymphoma Originating from the Left Atrium with Infiltration of Both Optic Nerves. A 48-year-old man was admitted because of an intracardiac tumor originating from the left atrium detected by chance. The patient had no symptoms associated with heart failure or arrhythmias. Transesophageal echocardiography revealed a large tumor mass probably encompassing the pulmonary veins. Due to this obstruction, a surgical exstirpation of the tumor was tried under cardiopulmonary bypass. But a resection of the tumor was not possible because of its large extension with diffuse cardiac infiltration. The histological diagnosis was non-Hodgkin(cid:29)s lymphoma of B-cell origin. Further lymphomatous lesions were detected in the abdomen. Combined chemotherapy was startet with partial remission at first. But the patient experienced a sudden bilateral visual loss. The funduscopy showed papilledema, hemorrhages of various types, and a cherry-red macula in association with tumoral optic nerve involvement. The retinal vessels were markedly narrowed or obliterated. The lumbar puncture revealed marked pleocytosis. The patient received whole brain irradiation together with intrathecal chemotherapy. However, there was no improvement in vision due to optic nerve atrophy. 5 months after admission, the patient died. Thus, even large cardiac tumors are often asymptomatic and detected by chance. Acute bilateral blindness caused by non-Hodgkin(cid:29)s lymphoma is a very rare disorder.
{"title":"Generalisiertes hochmalignes Non-Hodgkin-Lymphom mit Infiltration des linken Vorhofs und der Nervi optici mit bilateraler Amaurosis","authors":"M. Brück, U. Nixdorf, H. V. Korn, R. Feyrer, T. Papadopoulos, G. Helm, R. Janka, C. Mardin, V. Strnad, W. Daniel","doi":"10.1055/s-2000-10221","DOIUrl":"https://doi.org/10.1055/s-2000-10221","url":null,"abstract":"Zentralarterienverschluss – kirschroter Fleck – Amaurosis – Papillenatrophie Non-Hodgkin(cid:29)s Lymphoma Originating from the Left Atrium with Infiltration of Both Optic Nerves. A 48-year-old man was admitted because of an intracardiac tumor originating from the left atrium detected by chance. The patient had no symptoms associated with heart failure or arrhythmias. Transesophageal echocardiography revealed a large tumor mass probably encompassing the pulmonary veins. Due to this obstruction, a surgical exstirpation of the tumor was tried under cardiopulmonary bypass. But a resection of the tumor was not possible because of its large extension with diffuse cardiac infiltration. The histological diagnosis was non-Hodgkin(cid:29)s lymphoma of B-cell origin. Further lymphomatous lesions were detected in the abdomen. Combined chemotherapy was startet with partial remission at first. But the patient experienced a sudden bilateral visual loss. The funduscopy showed papilledema, hemorrhages of various types, and a cherry-red macula in association with tumoral optic nerve involvement. The retinal vessels were markedly narrowed or obliterated. The lumbar puncture revealed marked pleocytosis. The patient received whole brain irradiation together with intrathecal chemotherapy. However, there was no improvement in vision due to optic nerve atrophy. 5 months after admission, the patient died. Thus, even large cardiac tumors are often asymptomatic and detected by chance. Acute bilateral blindness caused by non-Hodgkin(cid:29)s lymphoma is a very rare disorder.","PeriodicalId":123656,"journal":{"name":"Tumordiagn u Ther","volume":"50 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2000-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121617435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Anamnese und klinischer Befund: Untersuchungen: Diagnose, Therapie und Verlauf: Folgerung: History and Clinical Findings: Investigations: Diagnosis, treatment and course: Conclusion:
诊断、治疗和康复:病史和临床表现;调查;诊断、治疗和病程;结论:
{"title":"Der Sister Mary Joseph's Nodule als Indikator eines metastasierten Ovarialkarzinoms","authors":"C. Michl, D. Bachter, H. Starz, B. Balda","doi":"10.1055/s-2000-8381","DOIUrl":"https://doi.org/10.1055/s-2000-8381","url":null,"abstract":"Anamnese und klinischer Befund: Untersuchungen: Diagnose, Therapie und Verlauf: Folgerung: History and Clinical Findings: Investigations: Diagnosis, treatment and course: Conclusion:","PeriodicalId":123656,"journal":{"name":"Tumordiagn u Ther","volume":"12 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2000-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134633638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
neu-rotoxischen (cid:220)berdosierungserscheinungen von Carbamaze-pin f(cid:252)hren.
《迷幻药》(cid:220)排出时间
{"title":"Relevante Wechselwirkungen von (Ko-) Analgetika mit anderen häufig in der Onkologie angewandten Substanzen","authors":"G. Tietze-Schillings, M. Kloke","doi":"10.1055/s-2000-7499","DOIUrl":"https://doi.org/10.1055/s-2000-7499","url":null,"abstract":"neu-rotoxischen (cid:220)berdosierungserscheinungen von Carbamaze-pin f(cid:252)hren.","PeriodicalId":123656,"journal":{"name":"Tumordiagn u Ther","volume":"269 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2000-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"134115817","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
P. Fürst, Adrian Brüngger, A. Brachat, Rita Grossenbacher, M. Kamke, J. Zimmermann, J. Heim
The development of miniaturized arrays, displaying thousands of genes on a surface smaller than a thumb-nail, can be regarded as a technological breakthrough of similar importance as the introduction of the PCR reaction. For the development of novel cancer treatment regimens, microarrays will in the future be indispensable in the elucidation of tumor development and progression, in the detection and monitoring of tumor heterogeneity, and the identification of putative risk factors. Microarrays will furthermore help in the identification of novel, more specific molecular targets crucial in the development of primary tumors as well as in the process of metastasis. In addition, multiparallel analysis of thousands of genes in tissues treated with putative anticancer drugs, will lead to a better, genome-wide understanding of the drugs efficacy, specificity and potentially harmful side-effects. The hope is to come up in the future with more potent and more specific anticancer agents at increased speed and chemical diversity. Die Entwicklung miniaturisierter angeordneter Muster von beispielsweise Nukleinsauren („microarrays”), mit denen sich tausende von Genen auf einer Flache kleiner als ein Daumennagel reprasentieren lassen, kann als ein technischer Durchbruch angesehen werden, der sich mit der Einfuhrung der PCR vergleichen lasst. Fur die Entwicklung neuer Tumortherapien werden Microarrays in Zukunft unverzichtbar sein fur die Analyse von Tumorentstehung und -progression, fur die Bestimmung der Heterogenitat im Tumor und bei der Identifizierung moglicher Risikofaktoren. Weiterhin werden Microarrays hilfreich sein bei der Definition neuer, spezifischerer Zielmolekule, die sowohl bei der Enstehung von Primartumoren als auch Metastasen eine Rolle spielen. Daruber hinaus wird die multiparallele Analyse tausender von Genen in Tumorgewebe unter Behandlung mit moglichen antineoplastischen Substanzen zu einem besseren, genomweiten Verstandnis der Effizienz, Spezifitat und moglicher unerwunschter Nebenwirkungen dieser Substanzen fuhren. Es besteht Hoffnung zu der Annahme, dass in Zukunft wirksamere und spezifischere Krebsmedikamente in kurzerer Zeit und mit hoherer chemischer Vielfalt entwickelt werden konnen.
小型化阵列的发展，在比拇指指甲还小的表面上显示数千个基因，可以被视为与PCR反应的引入同样重要的技术突破。为了开发新的癌症治疗方案，微阵列将在未来阐明肿瘤的发生和进展、检测和监测肿瘤异质性以及识别推定的危险因素方面发挥不可或缺的作用。微阵列将进一步帮助鉴定在原发性肿瘤的发展和转移过程中至关重要的新的、更特异性的分子靶点。此外，对使用假定的抗癌药物治疗的组织中的数千个基因进行多重并行分析，将导致对药物功效、特异性和潜在有害副作用的更好的全基因组理解。我们希望未来能以更快的速度和化学多样性开发出更有效、更特异的抗癌药物。micro - wicklung miniaturisierter angeordneter Muster von beispielsweise Nukleinsauren(“微阵列”)，mit denen sich tausende von Genen auf einer Flache kleiner als in Daumennagel representien lassen, mit entechnischer Durchbruch angesehen werden, mit der Einfuhrung der PCR vergleichen最后。肿瘤微阵列技术在肿瘤治疗中的应用，肿瘤进展分析，肿瘤异种生殖诊断，肿瘤风险鉴定。微阵列可用于定义肿瘤、特异性肿瘤、原发性肿瘤、转移瘤和Rolle肿瘤。肿瘤网络中基因的多并行分析:Behandlung mit moglichen anti - ineplastischen Substanzen zu einem besseren, Verstandnis der effizien, Spezifitat and moglicher ununschter Nebenwirkungen dieser Substanzen fuhren。他最喜欢的是在德国，在德国，在德国，在德国，在德国，在德国，在德国，在德国，在德国，在德国，在德国。
{"title":"High-density Microarray Technology in Cancer Research and Development","authors":"P. Fürst, Adrian Brüngger, A. Brachat, Rita Grossenbacher, M. Kamke, J. Zimmermann, J. Heim","doi":"10.1055/s-2000-7502","DOIUrl":"https://doi.org/10.1055/s-2000-7502","url":null,"abstract":"The development of miniaturized arrays, displaying thousands of genes on a surface smaller than a thumb-nail, can be regarded as a technological breakthrough of similar importance as the introduction of the PCR reaction. For the development of novel cancer treatment regimens, microarrays will in the future be indispensable in the elucidation of tumor development and progression, in the detection and monitoring of tumor heterogeneity, and the identification of putative risk factors. Microarrays will furthermore help in the identification of novel, more specific molecular targets crucial in the development of primary tumors as well as in the process of metastasis. In addition, multiparallel analysis of thousands of genes in tissues treated with putative anticancer drugs, will lead to a better, genome-wide understanding of the drugs efficacy, specificity and potentially harmful side-effects. The hope is to come up in the future with more potent and more specific anticancer agents at increased speed and chemical diversity. Die Entwicklung miniaturisierter angeordneter Muster von beispielsweise Nukleinsauren („microarrays”), mit denen sich tausende von Genen auf einer Flache kleiner als ein Daumennagel reprasentieren lassen, kann als ein technischer Durchbruch angesehen werden, der sich mit der Einfuhrung der PCR vergleichen lasst. Fur die Entwicklung neuer Tumortherapien werden Microarrays in Zukunft unverzichtbar sein fur die Analyse von Tumorentstehung und -progression, fur die Bestimmung der Heterogenitat im Tumor und bei der Identifizierung moglicher Risikofaktoren. Weiterhin werden Microarrays hilfreich sein bei der Definition neuer, spezifischerer Zielmolekule, die sowohl bei der Enstehung von Primartumoren als auch Metastasen eine Rolle spielen. Daruber hinaus wird die multiparallele Analyse tausender von Genen in Tumorgewebe unter Behandlung mit moglichen antineoplastischen Substanzen zu einem besseren, genomweiten Verstandnis der Effizienz, Spezifitat und moglicher unerwunschter Nebenwirkungen dieser Substanzen fuhren. Es besteht Hoffnung zu der Annahme, dass in Zukunft wirksamere und spezifischere Krebsmedikamente in kurzerer Zeit und mit hoherer chemischer Vielfalt entwickelt werden konnen.","PeriodicalId":123656,"journal":{"name":"Tumordiagn u Ther","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2000-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131180125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：